Gilead Pharmaceuticals announces first annual profit after $2bn in first-half profit
Gileidomide is an antiretroviral drug.Its main drug, the Sovaldi, has become the blockbuster drug of its time, but its makers are already paying a price.Gileadex, the UK-based maker of Sovaldi and a major US-based competitor, reported a third-quarter loss of $4.2bn, or 2.3%.The company has not released a full statement since it filed the financials.Analysts…